myBiometry providing the medical device to support to the asthma and COPD patients. Company has successfully completed its Seed funding round in which it raised 5 million dollars.
The round was conducted with Dexcom Ventures as a lead with CareSource Indiana, Elevate Ventures and other investors. These funds will be used to further the company’s efforts to bring the fenoTRACK device to the marketplace. This device is aimed at improving asthma and COPD patient care to be identified in advance.
Asthma and COPD are some of the common chronic diseases that affected hundreds of millions of peoples around the world, including 41 million people in the United States of America. these patients, approximately 40 to 50 percent may suffer from exacerbation or attacks in a year which accounts to millions of emergency department visits and hospital admissions in the U.S.
Type 2 inflammation stands as a predominant mediator in the development of these disorders with 80 percent of asthma patients and 30-40 percent of patients having COPD.
myBiometry is now concentrating on completing the development of its new fenoTRACK device which has been designed to assist in the monitoring and management of asthma and COPD. The purpose of this device is to aid patients in identifying pre incidences, and patient will able to take self care measures.
